IB Acquisition Corp. filings document the formal disclosure record of a SPAC, including trust-account amendments, deadline-extension mechanics, shareholder votes, material definitive agreements and capital-structure terms. The company’s reports describe common stock and rights listed on Nasdaq, with each right entitling the holder to receive one-twentieth of one share upon consummation of an initial business combination.
Its SEC record includes Form 8-K material-event reports and proxy materials covering special-meeting proposals, amendments to the Investment Management Trust Agreement, articles-of-incorporation changes, redemption and liquidation provisions, governance matters and business-combination related agreements.
IB Acquisition Corp. scheduled its 2026 annual meeting for December 16, 2026, at 10:00 a.m. Eastern Time, to be held virtually by live webcast. The record date for stockholders entitled to notice of and to vote at the meeting is the close of business on October 28, 2026.
Stockholder proposals for inclusion in the proxy statement must be received by close of business October 26, 2026. Nasdaq notified the company on October 5, 2026, that it was not in compliance with Listing Rule 5620(a) because it had not held an annual meeting within 12 months of its fiscal year-end. IB Acquisition believes the December meeting will enable it to regain compliance; it will be the company’s first annual meeting since its initial public offering.
IB Acquisition Corp. received a Nasdaq determination letter on October 5, 2026, stating that it is not compliant with the Annual Meeting Requirement because it did not hold an annual meeting of shareholders within 12 months of the end of its fiscal year. The company has 45 calendar days to submit a plan to regain compliance; if Nasdaq accepts the plan, Nasdaq may grant an exception of up to 180 calendar days from fiscal year-end, or until March 29, 2027, to regain compliance. The company intends to submit a plan that includes a proxy statement preparation and proxy solicitation timeline leading to an annual meeting. The notice has no immediate effect on listing or trading, and the common stock will continue trading as IBAC during the compliance period.
IB Acquisition Corp. stockholders approved an amendment extending the deadline for an initial business combination to March 28, 2027, or a later date approved by stockholders under the amended articles. It also sets redemption and liquidation procedures if no combination is completed by then.
Before the earliest of a business combination, specified 100% redemptions, or redemptions tied to certain amendment votes, trust funds will not be released except for interest used to pay franchise and income taxes. Public stockholders may redeem shares in connection with amendments changing the substance or timing of the obligation to redeem 100% of public shares, or other material pre-combination provisions, subject to the applicable limitation. At the September 24, 2026 meeting, 3,444,462 shares were represented, about 69% of shares outstanding on August 27, 2026; votes were 3,437,439 for, 4,523 against, and 2,500 abstentions. Holders redeemed 117,386 shares at approximately $10.97 each; approximately $1,288,199.54 will be paid, leaving approximately $7,042,627.97 in trust, subject to tax withdrawals.
IB Acquisition Corp. amended its pending business-combination arrangements with GNQ Insilico and disclosed a convertible-note financing and equity purchase facility. Under the Equity Purchase Facility Agreement, IBAC may, but is not obligated to, sell up to $50.0 million in aggregate gross purchase price of newly issued Class A common shares; the commitment period begins after the resale registration statement is declared effective and continues for up to 36 months. At the PIPE’s initial closing, the Buyer will purchase notes with an aggregate original principal amount of $16,470,588, with potential additional closings up to an aggregate principal amount of $90,000,000; the initial closing is conditioned on satisfaction or waiver of all business-combination conditions, including redomestication.
The PIPE Notes convert at an initial $10.00 per-share price, bear 12% annual interest (18% during a continuing event of default), and are secured by a first-priority interest in substantially all personal property. IBAC will issue a $675,000 convertible Commitment Note at business-combination closing for the facility. The amendment removes the Minimum Cash closing condition, requires outstanding Bridge Financing obligations to be exchanged for senior secured convertible notes at closing, and provides for issuance of 350,000 shares to the Buyer.
IB Acquisition Corp. entered into an agreement for an initial $16,470,588 aggregate original principal amount of senior secured convertible notes, with potential additional closings up to an aggregate principal amount of $90,000,000, in connection with its pending business combination with GNQ Insilico, Inc. The initial closing is conditioned on satisfaction or waiver of the business-combination closing conditions, including the company’s redomestication from Nevada to Delaware.
Separately, IB Acquisition Corp. may, but is not obligated to, sell up to $50.0 million in aggregate gross purchase price of newly issued Class A common stock through an equity purchase facility. Its commitment period begins when the resale registration statement is declared effective and continues for up to 36 months, subject to early termination. At the business-combination closing, the company will issue a $675,000 convertible Commitment Note. The notes carry 12% annual interest and an initial conversion price of $10.00 per share. The business-combination amendment removes the Minimum Cash closing condition, requires outstanding Bridge Financing obligations to be exchanged into senior secured convertible notes at closing, and provides for issuance of 350,000 shares to the Buyer. It also releases the Sponsor’s 610,500 Private Placement Units from a six-month lock-up restriction.
IB Acquisition Corp. filed a communication concerning an IBM-issued press release describing a collaboration among GNQ InSilico, IBM Consulting and AWS. The release describes GNQ’s BioAvatar, Q-BRM and BioVerdict products and an IBM-led professional-services offering through AWS Marketplace.
It says Q-BRM’s knowledge graph contains over 200 million causal relationships and describes three reasoning levels: observation, mechanism and causation. The release says the quantum-infused platform is not quantum-dependent and is production-ready on classical compute today, with quantum hardware used for selected molecular binding-energy and therapy-optimization problems. BioAvatar is described as creating biological and patient-specific digital representations; BioVerdict supports traceable outputs, GxP-compliant logging and 21 CFR Part 11 audit trails, with human review before submission.
IB Acquisition Corp. (IBAC) entered into several financing and structural agreements tied to its pending business combination with GNQ Insilico, Inc. It put in place a $50.0 million Equity Purchase Facility allowing sales of Class A common stock over up to 36 months, subject to a 4.99% (optionally 9.99%) beneficial ownership cap and a 19.99% exchange cap unless stockholders approve more. As consideration, IB Acquisition will issue a $675,000 convertible Commitment Note.
The company also agreed to issue senior secured convertible PIPE Notes, with an initial closing of $16,470,588 and potential additional closings up to $90,000,000, bearing 12% interest and convertible at $10.00 per share, secured by a first-priority lien on substantially all personal property. Registration rights agreements cover resale of equity from both the ELOC and PIPE. An amendment to the Business Combination Agreement removes the minimum cash closing condition, requires outstanding bridge financing to be exchanged into PIPE Notes at closing, provides 350,000 Class A shares to the PIPE buyer, and releases 610,500 sponsor private placement units from a six-month lock-up.
IB Acquisition Corp. (IBAC) announced multiple financing arrangements and amendments related to its pending business combination with GNQ Insilico Inc. The company entered into an Equity Purchase Facility giving it the right to sell up to $50.0 million of Class A common stock to an institutional investor over a commitment period of up to 36 months, subject to a 4.99%–9.99% beneficial ownership cap and a 19.99% exchange cap unless stockholders approve more. As consideration, IB Acquisition will issue a $675,000 convertible commitment note.
The company, GNQ and a buyer also signed a Securities Purchase Agreement for senior secured convertible notes, with an initial closing of $16,470,588 in principal and potential additional closings up to $90,000,000. These PIPE Notes bear 12% interest (increasing to 18% upon default), mature in 12 months, are convertible at an initial price of $10.00 per share, and are secured by a first-priority lien on substantially all personal property of IB Acquisition and its subsidiaries. An amendment to the Business Combination Agreement removes the minimum cash closing condition, requires outstanding bridge financing to roll into notes under this structure, and provides for the issuance of 350,000 Class A shares to the buyer, while releasing 610,500 sponsor private placement units from a six‑month lock‑up.
IB Acquisition Corp. (IBAC) is asking stockholders to approve several changes that would give the company more time to complete its initial business combination and avoid an automatic wind‑up. The main proposal extends the business‑combination deadline by six months, from September 28, 2026 to March 28, 2027, by amending the charter; this requires approval by holders of at least 65% of outstanding common shares, including Founder Shares.
A second proposal amends the Investment Management Trust Agreement so the Trust Account terms match the new deadline, and a third allows adjournment of the meeting if more time is needed to solicit votes. Public stockholders may redeem their shares in connection with the extension for cash equal to their pro rata share of the Trust Account, which held approximately $8.3 million as of the record date, implying an expected redemption price of about $10.93 per share. If the extension is not approved and no business combination closes by September 28, 2026, IB Acquisition must redeem 100% of public shares from the Trust Account and then dissolve, leaving only liquidation value and no future upside from any potential transaction.
IB Acquisition Corp. (IBAC) is calling a virtual special meeting on September 24, 2026 to ask stockholders to approve three proposals focused on extending its timeframe to complete an initial business combination and aligning its trust terms with that extension.
Proposal 1 (Extension Proposal) would amend the charter to extend the deadline to complete a business combination by six months, from September 28, 2026 to March 28, 2027, at the company’s election. Approval requires the affirmative vote of 65% of all outstanding common shares, including founder shares. Public stockholders will have the right to redeem their public shares for cash in connection with the extension and again in connection with any later business combination vote or a future liquidation. The company must maintain at least $5,000,001 of net tangible assets after redemptions to proceed with the extension.
Proposal 2 (Trust Amendment Proposal) would amend the Investment Management Trust Agreement so the trust can operate consistently with the extended deadline. It requires approval by a majority of outstanding common shares. Proposal 3 would allow adjournment of the meeting if there are insufficient votes for Proposals 1 or 2. As of the record date, there were 5,008,229 shares outstanding and insiders and related parties held 3,613,590 shares (about 63.0%). If the extension is not approved and no business combination closes by September 28, 2026, IBAC states it will redeem 100% of public shares from the trust and liquidate.